These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Aquaporin-4 and Parkinson's Disease. Lapshina KV; Ekimova IV Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338949 [TBL] [Abstract][Full Text] [Related]
8. Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics. Belaidi AA; Bush AI J Neurochem; 2016 Oct; 139 Suppl 1():179-197. PubMed ID: 26545340 [TBL] [Abstract][Full Text] [Related]
9. α-Synuclein ubiquitination and novel therapeutic targets for Parkinson's disease. Rott R; Szargel R; Shani V; Bisharat S; Engelender S CNS Neurol Disord Drug Targets; 2014; 13(4):630-7. PubMed ID: 24168368 [TBL] [Abstract][Full Text] [Related]
10. Does the oxysterol 27-hydroxycholesterol underlie Alzheimer's disease-Parkinson's disease overlap? Marwarha G; Ghribi O Exp Gerontol; 2015 Aug; 68():13-8. PubMed ID: 25261765 [TBL] [Abstract][Full Text] [Related]
11. Toll-like receptor expression in the blood and brain of patients and a mouse model of Parkinson's disease. Drouin-Ouellet J; St-Amour I; Saint-Pierre M; Lamontagne-Proulx J; Kriz J; Barker RA; Cicchetti F Int J Neuropsychopharmacol; 2014 Dec; 18(6):. PubMed ID: 25522431 [TBL] [Abstract][Full Text] [Related]
12. Activating Autophagy as a Therapeutic Strategy for Parkinson's Disease. Fowler AJ; Moussa CE CNS Drugs; 2018 Jan; 32(1):1-11. PubMed ID: 29492779 [TBL] [Abstract][Full Text] [Related]
13. Dysfunction of dopamine homeostasis: clues in the hunt for novel Parkinson's disease therapies. Bisaglia M; Greggio E; Beltramini M; Bubacco L FASEB J; 2013 Jun; 27(6):2101-10. PubMed ID: 23463698 [TBL] [Abstract][Full Text] [Related]
14. Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. Dehay B; Bourdenx M; Gorry P; Przedborski S; Vila M; Hunot S; Singleton A; Olanow CW; Merchant KM; Bezard E; Petsko GA; Meissner WG Lancet Neurol; 2015 Aug; 14(8):855-866. PubMed ID: 26050140 [TBL] [Abstract][Full Text] [Related]
15. The Role of Lipids Interacting with α-Synuclein in the Pathogenesis of Parkinson's Disease. Galvagnion C J Parkinsons Dis; 2017; 7(3):433-450. PubMed ID: 28671142 [TBL] [Abstract][Full Text] [Related]
16. l-3,4-dihydroxyphenylalanine (l-DOPA) modulates brain iron, dopaminergic neurodegeneration and motor dysfunction in iron overload and mutant alpha-synuclein mouse models of Parkinson's disease. Billings JL; Gordon SL; Rawling T; Doble PA; Bush AI; Adlard PA; Finkelstein DI; Hare DJ J Neurochem; 2019 Jul; 150(1):88-106. PubMed ID: 30716176 [TBL] [Abstract][Full Text] [Related]